<DOC>
	<DOCNO>NCT01192880</DOCNO>
	<brief_summary>This Phase 3 , multi-center , randomize , double blind , parallel-group , placebo-controlled study evaluate efficacy safety RO4917838 ( bitopertin ) participant persistent , predominant negative symptom schizophrenia . Participants , stable treatment antipsychotic , randomize receive daily oral dos RO4917838 match placebo 52 week , follow optional treatment extension 3 year .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Bitopertin Participants With Persistent , Predominant Negative Symptoms Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Based screening Structured Clinical Interview Statistical Manual Mental Disorders , 4th Edition ( DSM IV ) Clinical Trial ( SCID CT ) , DSMIV Text Revision ( DSMIVTR ) diagnosis schizophrenia , paranoid , disorganize , residual , undifferentiated catatonic subtype A score 40 great sum 14 PANSS negative disorganize thought factor item ( item score 17 maximum possible score 98 ) A score 22 less sum 8 PANSS positive symptom factor item . The score item P1 ( delusion ) , P3 ( hallucinatory behavior ) , P6 ( suspiciousness ) G9 ( unusual thought content ) meet following requirement : 2 item score 4 ; item score less 5 Clinical stability 6 month prior randomization well antipsychotic treatment stability past 8 week time randomization Are least moderately ill , defined Clinical Global Impression Severity ( CGI S ) negative symptom score equal ( &gt; /= ) 4 Stable dos anticholinergic , antidepressive medication least 8 week prior randomization allow long respective scale cutoff entry criterion meet With exception clozapine , participant available marketed atypical typical antipsychotic ( treatment maximum 2 antipsychotic ) Have caregiver consider reliable investigator Female participant either surgically sterile postmenopausal must agree use least one effective form contraception agree remain sexually abstinent screen 90 day completion study medication Evidence participant clinically significant , uncontrolled unstable disorder ( example , cardiovascular , renal , hepatic disorder ) Body Mass Index ( BMI ) less ( &lt; ) 17 ( &gt; ) 40 kilogram per meter square ( kg/m^2 ) Depressive symptom , define score 9 great Calgary Depression Rating Scale Schizophrenia ( CDSS ) A severity score &gt; /=3 Parkinsonism item Extrapyramidal Symptoms Rating Scale Abbreviated ( ESRSA ) ( Clinical Global Impression , Parkinsonism ) Positive result serum pregnancy test breast feeding screening , intend become pregnant course trial . History neuroleptic malignant syndrome ( NMS ) Based DSMIVTR criterion screen SCIDCT : current DSMIVTR Axis I diagnosis ; alcohol substance dependence within 12 month abuse within 3 month exception nicotine ; dementia , delirium amnestic disorder per DSMIVTR Treated electroconvulsive therapy ( ECT ) within 6 month prior randomization Ever receive RO4917838 another glycine transporter 1 ( GLYT 1 ) inhibitor Require high dos benzodiazepine ( &gt; 4 mg per day lorazepam equivalent ) Have positive urine drug screen amphetamine ( include 3,4Methylenedioxymethamphetamine [ MDMA ] /ecstasy ) , cocaine , barbiturate , cannabis and/or opiate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>